Nivolumab in Advanced Hodgkin’s Lymphoma | NEJM

43 - Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s LymphomaПодробнее

ASCO 2023 Highlights on nivolumab in advanced stage classic Hodgkin Lymphoma: the SWOG S1826 studyПодробнее

Nivolumab + chemotherapy in previously untreated stage III or IV Hodgkin lymphomaПодробнее

NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaПодробнее

Immunotherapy breakthrough in Hodgkin lymphoma patients | Dana-Farber Cancer InstituteПодробнее

Oncology beyond the Obvious Webinar Series 32Подробнее

CHECKMATE 205: does nivolumab improve the long-term outcomes of patients with advanced stage cHL?Подробнее

Perioperative Nivolumab in Resectable NSCLC | NEJMПодробнее

Updates on the use of nivolumab in Hodgkin lymphoma & how this agent may impact treatmentПодробнее

SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphomaПодробнее

Hodgkin’s Lymphoma Treatment Adapted after Interim PET-CTПодробнее

CheckMate 205: 5 year follow-up of nivolumab in HLПодробнее

Checkmate 205: the use of nivolumab to treat relapsed Hodgkin lymphomaПодробнее

Evaluating the combination of nivolumab and lenalidomide in relapsed HL and LBCLПодробнее

Nivolumab shows early promise in Hodgkin lymphomaПодробнее

Phase I study shows nivolumab is safe and tolerable for relapsed or refractory Hodgkin lymphomaПодробнее

Novel agents for the treatment of Hodgkin lymphoma: brentuximab vedotin and nivolumabПодробнее

Results of SWOG S1826 Study, showing Nivo-AVD better than BV-AVD in Hodgkin's Lymphoma patientsПодробнее

Phase I trial of nivolumab shows significant benefit for Hodgkin's lymphoma, Mayo ClinicПодробнее

NIVAHL: nivolumab and AVD in early-stage unfavorable HLПодробнее

Checkmate 205 study results: nivolumab in classical Hodgkin LymphomaПодробнее